(NASDAQ: PRLD) Prelude Therapeutics's forecast annual revenue growth rate of 89.22% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.49%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.23%.
Prelude Therapeutics's revenue in 2026 is $16,720,000.On average, 5 Wall Street analysts forecast PRLD's revenue for 2026 to be $2,957,070,958, with the lowest PRLD revenue forecast at $0, and the highest PRLD revenue forecast at $8,747,444,068. On average, 5 Wall Street analysts forecast PRLD's revenue for 2027 to be $2,707,940,438, with the lowest PRLD revenue forecast at $0, and the highest PRLD revenue forecast at $8,362,757,235.
In 2028, PRLD is forecast to generate $10,662,913,701 in revenue, with the lowest revenue forecast at $4,878,275,054 and the highest revenue forecast at $16,725,514,470.